The combination of ledipasvir + sofosbuvir was highly effective in a small study of people with HCV genotype 6.
Researchers recruited 25 participants with the following average profile:
After 12 weeks of ledipasvir + sofosbuvir, 96% (24 of 25 participants) achieved an SVR12.
At this time further information about the trial is not available. However, note that the study was small and the results, although very promising, require confirmation in a larger clinical trial.
Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infections. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract LB-11.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|